- This event has passed.
The Potential of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer – From Mechanism to Action
August 8 @ 6:00 pm - 7:00 pm CEST
Supported by an independent educational grant from Daiichi Sankyo
Newly emerging antibody-drug conjugates (ADCs) have the potential to dramatically impact outcomes for patients with advanced non-small cell lung cancer (NSCLC). Join our distinguished faculty experts for an interactive educational symposium as they address the rationale for the development of ADCs, dive deep into the latest clinical evidence, and discuss future directions for clinical practice.
**Target audience** This activity is intended for an international audience of hematology/oncology specialists, pathologists, pulmonologists, and other members of the oncology care team.
**Accreditation** The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).
Satellite CME Symposium by Medscape Oncology Global
This program was approved by the IASLC 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.
Hossein Borghaei DO, MS
Fox Chase Cancer Center
Department of Hematology/Oncology
Philadelphia, PA, United States
Ticiana Leal MD
Winship Cancer Institute Emory University
Department of Hematology & Oncology
Atlanta, GA, United States
Antonio Passaro MD, PhD
IRCCS European Institute of Oncology
Division of Thoracic Oncology